Show simple item record

dc.contributor.authorSkarlos, Dimosthenis V.en
dc.contributor.authorDimopoulos, M. A.en
dc.contributor.authorKosmidis, Paraskevas A.en
dc.contributor.authorPapakostas, P.en
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorBacoyiannis, Charalambosen
dc.contributor.authorKiamouris, Chen
dc.contributor.authorKlouvas, G. D.en
dc.contributor.authorGogas, H.en
dc.contributor.authorFountzilas, Georgeen
dc.contributor.authorSamantas, E.en
dc.creatorSkarlos, Dimosthenis V.en
dc.creatorDimopoulos, M. A.en
dc.creatorKosmidis, Paraskevas A.en
dc.creatorPapakostas, P.en
dc.creatorPavlidis, Nicholasen
dc.creatorBacoyiannis, Charalambosen
dc.creatorKiamouris, Chen
dc.creatorKlouvas, G. D.en
dc.creatorGogas, H.en
dc.creatorFountzilas, Georgeen
dc.creatorSamantas, E.en
dc.date.accessioned2018-06-22T09:53:15Z
dc.date.available2018-06-22T09:53:15Z
dc.date.issued2003
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41735
dc.description.abstractThere is some evidence that taxanes and gemcitabine are effective antitumor agents against small-cell lung cancer (SCLC). A total of 20 chemotherapy-naive patients with extensive disease (ED) SCLC, were treated as a part of the first step of a phase II study, with docetaxel 50 mg/m2 and gemcitabine 1000 mg/m2, both administered on day 1 and 8 every 3 weeks up to a total of six cycles. For patients who progressed after the first cycle or had stable disease after the second cycle of chemotherapy, protocol treatment was stopped and further treatment with the standard cisplatin or carboplatin-etoposide combination was administered. Patients were in the vast majority male smokers with a good performance status. A total of 72 cycles was delivered while patients managed to receive the 78 and 84% of the planned dose of docetaxel and gemcitabine, respectively. Only six patients responded partially and the trial ended prematurely since at least seven responses were required among the first 19 patients. With a median follow-up of 13 months, median time to progression (TTP) was 8 months and median survival 9.6 months. Hematological and non-hematological toxicity was generally acceptable while patients tolerated their treatment reasonably well. In conclusion, docetaxel-gemcitabine showed a modest response rate in chemotherapy-naive patients with ED SCLC. © 2003 Elsevier Science Ireland Ltd. All rights reserved.en
dc.language.isoengen
dc.sourceLung Canceren
dc.subjectArticleen
dc.subjectOrganizationen
dc.subjectCancer chemotherapyen
dc.subjectCisplatinen
dc.subjectEtoposideen
dc.subjectHumanen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectFemaleen
dc.subjectOncologyen
dc.subjectCancer growthen
dc.subjectCancer survivalen
dc.subjectCarboplatinen
dc.subjectFollow upen
dc.subjectPriority journalen
dc.subjectClinical trialen
dc.subjectDocetaxelen
dc.subjectPhase 2 clinical trialen
dc.subjectDrug tolerabilityen
dc.subjectTreatment outcomeen
dc.subjectLung small cell canceren
dc.subjectMaleen
dc.subjectToxicityen
dc.subjectSmokingen
dc.subjectGemcitabineen
dc.subjectClinical protocolen
dc.subjectPerformanceen
dc.subjectExtensive small cell lung canceren
dc.titleDocetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Groupen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/S0169-5002(03)00154-5
dc.description.volume41
dc.description.issue1
dc.description.startingpage107
dc.description.endingpage111
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.gnosis.orcid0000-0002-2195-9961


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record